Targeting Inflammatory and Fibrotic Pathways in SSc-ILD

Released On
July 9, 2021

Last Reviewed
July 2, 2021

Expires On
July 9, 2022

Media Type

Completion Time
1.25 hours

Dermatology, Pathology, Primary Care, Pulmonology, Radiology, Rheumatology

Pulmonary Fibrosis, Respiratory

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Paradigm Medical Communications, LLC. In collaboration with the Pulmonary Fibrosis Foundation.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to address the educational needs of academic and community-based pulmonologists and rheumatologists. It may also benefit pathologists, radiologists, dermatologists, primary care physicians, nurse practitioners, PAs, pharmacists, nurses, residents, fellows, and other healthcare professionals involved in the care of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Program Overview

Scleroderma or systemic sclerosis (SSc) is a rare autoimmune disorder characterized by fibrosis in the skin and internal organs, including the lungs, that results in increased morbidity and mortality for patients. SSc-ILD occurs in the majority of patients. Due to the rarity of the disease and the heterogeneity of symptoms, patients often experience diagnostic delay until referral to an appropriate specialist, thus delaying the opportunity for early treatment. For patients with risk factors for severe interstitial lung disease (ILD), rapid progression often occurs within the first 5 years from diagnosis. There is no curative treatment for SSc, but immunosuppressive agents and now antifibrotics are available to delay the progression of SSc-ILD. Patients with SSc need appropriate screening and monitoring for ILD. Patients presenting with ILD need appropriate screening for SSc, so that appropriate therapy can be initiated. Data are emerging for additional anti-inflammatory therapies that impact fibrosis, including tocilizumab and rituximab, as well as pirfenidone, an antifibrotic with efficacy in other forms of ILD. In this webinar diagnosis of SSc-ILD is reviewed for patients presenting with SSc and those presenting with ILD. Data for immunotherapies and antifibrotics are discussed, along with selecting therapy based on individual patient characteristics and risk factors for disease progression.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Outline risk factors for progressive SSc-ILD
  • Assess recommended monitoring for patients with scleroderma and SSc-ILD
  • Select appropriate, evidence-based therapy for patients who have SSc-ILD



Fernando Jose Martinez, MD, MS

Bruce Webster Professor of Internal Medicine
Chief, Division of Pulmonary and Critical Care Medicine
Weill Cornell Medicine
New York, NY

Elizabeth R. Volkmann, MD, MS

Assistant Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, UCLA CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
David Geffen School of Medicine
Los Angeles, CA

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education

PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosures of Conflicts of Interest

In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been resolved.

Fernando Jose Martinez, MD, MS

  • Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb Company; DevPro Biopharma LLC; Sanofi-aventis U.S. LLC; Shionogi Inc.; United Therapeutics Corporation; Veracyte, Inc.
  • Grant/Research Support: Afferent Pharmaceuticals/Merck & Co, Inc; Bayer Corporation; Biogen-Idec; Respivant Sciences Company; Roche


Elizabeth R. Volkmann, MD, MS

  • Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc
  • Grant/Research Support: Bristol Myers Squibb Company; Corbus Pharmaceuticals Holdings, Inc; Forbius; Kadmon Holdings, Inc.

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.

Resolution of Conflict of Interest

Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Instructions for Participation and Credit

To receive a CME certificate of participation, you should:

  • Follow instructions to register or log in with your professional information and complete the preactivity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or

There is no fee required for participation in this activity.

Course Viewing Requirements

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here:

Technical Support:
If you have any technical problems or playback issues, email us at

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.


This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Contact Information

If you have any questions or comments, please email us at